NIIMBL
announced 8 new technology and workforce projects in May 2026, including an enhanced end-to-end manufacturing testbed for fast, flexible drug-substance manufacturing.
- Country
- United States
US
Coverage
| EU | US | |
|---|---|---|
| automation-robotics | ✓ | ✓ |
Regulatorsfdaema
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Scale-up centers for innovative biologic small-batch production | automation-robotics | Low | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.